Pipeline
Precision oncology therapeutics targeting critical drivers of tumor proliferation, survival, and therapeutic resistance.
Alaw Therapeutics is developing a next-generation precision oncology pipeline of highly selective small-molecule inhibitors designed to address key mechanisms of tumor progression, therapeutic resistance, and intracranial disease.
Our pipeline targets high-value oncogenic dependencies that drive cell-cycle progression and growth-factor signaling across aggressive solid tumors, including cancers with CNS involvement and brain metastases.
Tumors can evade existing therapies through multiple mechanisms, including compensatory cell-cycle activation, acquired mutations, pathway reactivation, and adaptive signaling. Alaw’s approach is designed to address these mechanisms through differentiated selectivity, broad mutational coverage, and CNS penetration.
Our pipeline includes:
AL-433: Selective, brain-penetrant CDK4 inhibitor
Designed to control CDK4-dependent cell-cycle progression while sparing CDK6, with the potential to reduce CDK6-associated hematologic toxicity and enable sustained target inhibition.
AL-273: Next-generation pan-mutant EGFR inhibitor
Designed to target a broad spectrum of clinically relevant EGFR mutations, including difficult-to-treat and resistance-associated variants, with the goal of providing durable pathway suppression across genetically diverse EGFR-driven tumors.
AL-605: Selective, brain-penetrant CDK2 inhibitor
Designed to target CDK2-dependent tumor proliferation, including Cyclin E-driven cancers and settings where CDK2 activation contributes to therapeutic resistance.
Through differentiated selectivity, CNS penetration, and precision targeting of key oncogenic dependencies, Alaw aims to develop transformative therapies for patients with resistant and aggressive cancers where existing treatment options remain limited.